Benchmark lowered the firm’s price target on AbCellera to $12 from $20 and keeps a Buy rating on the shares after the company reported Q2 results. Management did not provide detailed financial guidance going forward, notes the firm, which cites reduced valuations for other drug discovery stocks for its lower AbCellera target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABCL: